Prof Mateos speaks with ecancer at the 16th International Myeloma Workshop about an overview of sessions at IMW 2017, first discussing the rationale and mechanism of action for monoclonal antibodies (mAbs) in the treatment of myeloma.
She then focuses on the clinical impact of some mAbs, including elotuzumab, daratumumab, isatuximab and checkpoint inhibitors.
An overview of some of the key results for these treatments are discussed, highlighting the benefits that mAbs can provide to multiple myeloma patients.
Summarising the future role of mAbs, it is suggested that results coming from daratumumab show that it should be a backbone to which the backbone regimes should be added.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.